Aardvark Therapeutics Inc AARD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
-
FDA Lifts Aardvark Therapeutics Clinical Hold, Shares Rise
-
Aardvark Therapeutics: FDA Lifts ARD-101 Clinical Halt
-
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
-
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
-
AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
-
AARD FINAL DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
-
Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD
Trading Information
- Previous Close Price
- $3.95
- Day Range
- $1.39–3.00
- 52-Week Range
- $1.39–16.60
- Bid/Ask
- $1.40 / $1.42
- Shares Outstanding
- 21.88M
- Market Cap
- $30.42M
- Volume/Avg
- 16M / 394,913
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 28
Valuation
|
Metric
|
AARD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.41 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AARD
|
|---|---|
Quick Ratio | 11.57 |
Current Ratio | 12.63 |
Interest Coverage | — |
Quick Ratio
AARD
Profitability
|
Metric
|
AARD
|
|---|---|
Return on Assets (Normalized) | −54.38% |
Return on Equity (Normalized) | −59.56% |
Return on Invested Capital (Normalized) | −63.09% |
Return on Assets
AARD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|JLh$TD | LOCK|nw?v@ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$K^Myc | LOCK|>VM@z | $83B | |||
| Moderna Inc
MRNA
| LOCK|>YYk<# | LOCK|Jc< | $80B | |||
| argenx SE ADR
ARGX
| LOCK|&m@!zKD | LOCK|^qQ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#WkMl>T | LOCK|S&% | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$WM&@!$ | LOCK|gncDQ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|x#Wh^f& | LOCK|Yl#J | $28B | |||
| Incyte Corp
INCY
| LOCK|^@!m^zB | LOCK|#$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|V#?%@J | LOCK|t$! | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|hXxV&%H | LOCK|RQ | $14B |
United States